February 9, 2026, Shenzhen - Shenzhen Xihe Life Technology Co., Ltd., led by Shenzhen Weiguang Biological Products Co., Ltd. and jointly established by Shenzhen Shenye Biopharmaceutical Industry Development Co., Ltd., Shenzhen Cell Valley Biomedicine Co., Ltd. and Shenzhen Saiqiao Biotechnology Co., Ltd., completed its industrial and commercial registration, marking the official launch of the construction of a market-oriented public service platform for cell and gene therapy (CGT) in Shenzhen.

According to public information, Shenzhen Xihe Life Technology Co., Ltd. has a registered capital of 100 million yuan. In this four-party joint investment, Weiguang Biology subscribed for 40 million yuan, holding 40% of the shares, and is the leader of the platform; Shenye Biotechnology holds 39% of the shares, relying on Shenzhen’s state-owned assets system, and is the platform leader. Taiwan provides policy coordination and capital resource support; Shenzhen Cell Valley holds 11% of the shares. As a core service provider of clinical-grade viral vectors and cell preparations that are scarce in China, it is responsible for the construction of key technical capabilities of the platform; Saiqiao Biotech holds 10% of the shares and is responsible for the localization support of CGT core process equipment and consumables.

Shenzhen Xihe Life Technology Co., Ltd. is positioned as a market-oriented public service platform for cell and gene therapy, focusing on the key links of the entire industry chain of "plasmids-viral vectors-cell drugs", and provides compliant, standardized, and scalable CGT R&D, transformation and preparation services to hospitals, scientific research institutions, biopharmaceutical companies and innovation teams.

The core goal of the platform is to solve the three common problems in the current development of the CGT industry:

· Difficulty in large-scale production

· High manufacturing costs

· Inconsistent process and quality standards

By integrating state-owned platforms, clinical-grade manufacturing capabilities, localization of core equipment and GMP systematic management experience, CGT will be promoted from a "scientific research exploration" to an industrialization stage that is "replicable, affordable and promoteable".

As one of the important technical shareholders of this joint venture, Shenzhen Cell Valley is one of the first professional platform companies in China with GMP industrial production capabilities for clinical-grade retroviral vectors. It has built more than 100 clinical-grade viral vector resource libraries covering multiple types of application scenarios such as CAR-T, TCR-T, NK, γδT, etc., and has significant first-mover and scale advantages in the underlying manufacturing process of CGT.

In the platform construction of Shenzhen Xihe Life Technology Co., Ltd., Shenzhen Cell Valley will focus on:

· Construction of large-scale preparation and quality control system of clinical-grade viral vectors

· Cellular drug GMP production process and quality standard output

· The key support for the CGT project to transform from IIT to standardized clinical practice under the New Deal of the State Council Order No. 818

Through the public service platform model, the original highly dispersed and costly underlying manufacturing capabilities are transformed into industry-shareable infrastructure, and the comprehensive threshold for innovative entities to enter the CGT track is lowered.

The joint venture to establish Shenzhen Xihe Life Technology Co., Ltd. is also a strategic extension of Weiguang Biotech to the trillion-level new track of cell and gene therapy on the basis of consolidating its main business of blood products. Relying on its GMP management experience and quality system capabilities accumulated in the field of blood products for more than 40 years, Weiguang Biotech is accelerating the construction of a second growth curve.

 At the same time, as an important industrial platform of Shenzhen's state-owned assets system, Shenye Biotechnology will help Xihe Life to build an important infrastructure platform for the CGT industry in Shenzhen and even the Guangdong-Hong Kong-Macao Greater Bay Area through policy coordination, resource integration and long-term capital support.

 The establishment of Shenzhen Xihe Life Technology Co., Ltd. marks that Shenzhen has taken the lead in exploring and forming a new development model of "public construction and private operation, platform-based operation, and market-oriented services" in the field of cell and gene therapy. Under this model, state-owned assets and leading enterprises jointly "build platforms and foundations", and market entities with core technologies and industrialization capabilities are responsible for "strengthening operations and improving efficiency" to achieve an organic integration of public attributes and market mechanisms.

This "public construction and private operation" model has effectively solved the structural problems that the CGT industry has long faced, such as heavy asset investment, difficulty in independent responsibilities for single institutions, and difficulty in efficient conversion of public resources. It provides a realistic path for cell and gene therapy to move from scientific research exploration to large-scale clinical application and standardized marketization.

In the future, Shenzhen Cell Valley will rely on the public service platform of Xihe Life to continue to export key underlying capabilities such as viral vectors and cell preparation, and work with all parties to build this model into a replicable and promoteable "Shenzhen Model", providing demonstration experience of institutional innovation and industrial practice for the high-quality development of the national cell and gene therapy industry.

微信公众号

市场部：赖女士